KCP
REGN icon

Kera Capital Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Kera Capital Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Sell
377
-216
-36% -$147K 0.02% 557
2026
Q1 		$458K Buy
593
+118
+25% +$90.3K 0.06% 282
2025
Q4 		$352K Sell
475
-24
-5% -$16.3K 0.04% 355
2025
Q3 		$281K Buy
+499
New +$282K 0.04% 310

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Kera Capital Partners's REGN Position: Q2 2026 in Review

Kera Capital Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 36% in Q2 2026, selling an estimated $147K and leaving 377 shares worth $235K. The position accounts for 0.02% of the portfolio, ranked #557.

Kera Capital Partners first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $458K in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Kera Capital Partners held 377 shares of Regeneron Pharmaceuticals worth $235K as of Q2 2026.
  • Kera Capital Partners sold 216 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $147K.
  • Regeneron Pharmaceuticals made up 0.02% of Kera Capital Partners's portfolio in Q2 2026, its #557 holding.
  • Kera Capital Partners first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Kera Capital Partners's Regeneron Pharmaceuticals position peaked at $458K in Q1 2026.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Kera Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.